Table 5 Linear regression analyses of baseline values and percent changes in clinical factors affecting the percent change in sd LDL-C levels

BMI (kg/m²)

46

0.04

−1.07 ~ 1.37

0.8

Gender (Male = 1, Female = 2)

47

−0.18

−17.18 ~ 4.34

0.24

44

−0.11

−16.4 ~ 8.13

0.5

Age (year)

47

−0.1

−0.72 ~ 0.36

0.5

Body weight (kg)

47

0.18

−0.13 ~ 0.56

0.22

44

0.03

−0.38 ~ 0.44

0.88

Abdominal girth (cm)

45

0.08

−0.44 ~ 0.74

0.61

HbA1c (%)

47

0.2

−2.07 ~ 11.1

0.17

44

0.19

−2.54 ~ 11.1

0.21

Uric acid (mg/dL)

47

0.1

−2.45 ~ 5.02

0.49

TC (mg/dL)

47

−0.42

−0.41 ~ −0.09

0.004

44

−0.43

−0.46 ~ −0.06

0.01

LDL-C (mg/dL)

47

-0.29

−0.34 ~ −0.002

0.05^d

TG (mg/dL)

47

−0.18

−0.12 ~ 0.03

0.23

44

−0.04

−0.09 ~ 0.07

0.8

HDL-C (mg/dL)

47

−0.24

−0.66 ~ 0.06

0.11

44

−0.02

−0.45 ~ 0.41

0.92

sd LDL-C (mg/dL)

47

−0.42

−0.68 ~ −0.14

0.004^d

ApoA-I (mg/dL)

47

−0.22

−0.36 ~ 0.05

0.14^e

CETP (μg/mL)

44

0.29

−0.15 ~ 18.67

0.054

44

0.32

0.27 ~ 20.2

0.04

Pioglitazone use

47

0.02

−14.13 ~ 16.5

0.88

Change in Body weight (%)

47

0.35

0.05 ~ 4.29

0.02

43

0.43

1.24 ~ 5.26

0.002

Change in HbA1c (%)

47

−0.13

−1.2 ~ 0.23

0.37

Change in Uric acid (%)

47

0.12

−0.22 ~ 0.56

0.41

Change in TG (%)

46

0.32

0.01 ~ 0.2

0.03

43

0.26

−0.0001 ~ 0.16

0.05

Change in HDL-C (%)

47

0.011

−0.42 ~ 0.61

0.94

Change in ApoA-I (%)

46

0.11

−0.31 ~ 1.28

0.48

Change in CETP (%)

44

0.32

0.03 ~ 0.6

0.03

43

0.46

0.19 ~ 0.66

0.001